Dual Aging Therapy Boosts Lifespan 70% in Preclinical Study
Clearing zombie cells then restoring stem cell activity produced far greater lifespan gains than either approach alone.
20 articles
Clearing zombie cells then restoring stem cell activity produced far greater lifespan gains than either approach alone.
A new wave of biotechs is targeting aging as a root cause, using encapsulated cells and gene therapy to restore lost proteins and reverse decline.
Geroscience pioneer Dr Nir Barzilai explains how intervening in aging biology โ not individual diseases โ may be medicine's biggest leap.
From an $80M genetics study to a single-injection heart therapy, new research is redefining what drives exceptional human lifespan.
An $80M family study, 37 proteins in centenarian blood, and a call to treat aging as a systems failure converge in new research.
An $80M family study, 37 proteins in centenarian blood, and a call to rethink aging as a systems failure โ here's what's new.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Immorta Bio combines senolytics and stem cell revival with AI to achieve 70%+ lifespan extension in animal models.
XPRIZE Healthspan pits 10 teams against each other to restore muscle, cognition, and immunity in older adults by 2030.
Tumor-infiltrating lymphocyte therapies are emerging as a powerful cancer treatment. Here's what the science says and why it matters for longevity.
A single FGF21 gene injection in aging mice extended median lifespan by 20%, reversing fat gain, inflammation, and organ decline.
The largest epigenetic testing merger yet aims to connect biological age scores directly to personalized interventions and supplements.
Seragon's oral combo therapy SRN-901 outperforms rapamycin in mice, boosting lifespan and slashing frailty through multi-pathway aging intervention.
From NAD+ restoring aged muscle to meal timing accelerating aging, April's research roundup delivers actionable longevity insights.
Intellia's in vivo CRISPR treatment edits genes directly inside living patients and just cleared a Phase 3 trial โ a world first.
PARP inhibitors have transformed cancer treatment, but resistance and toxicity are emerging as serious limits to their long-term effectiveness.
From a massive family study of centenarians to a paradigm shift in how aging is measured, longevity science is evolving fast.
NewLimit's liver-targeting epigenetic reprogramming therapy heads to clinical trials after preclinical results arrived years ahead of schedule.
Scientists boosted a protein that dampens chronic inflammation, and older mice grew stronger, more energetic, and had healthier bones.
Intellia's one-time in vivo CRISPR therapy achieved an 87% attack reduction in Phase 3, marking genetic medicine's biggest clinical milestone yet.